Drug nanocrystals: In vivo performances.
暂无分享,去创建一个
Lei Gao | Guiyang Liu | Xiaoqing Wang | Jianli Ma | Liang Zhou | Xiang Li | Lei Gao | Guiyang Liu | Jianli Ma | Xiaoqing Wang | Liang Zhou | Xiang Li
[1] Gordon L. Amidon,et al. Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size , 1996, Pharmaceutical Research.
[2] Xueming Li,et al. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats , 2009, Drug development and industrial pharmacy.
[3] L. Yahia,et al. Therapeutic potential of nanoparticulate systems for macrophage targeting. , 2005, Biomaterials.
[4] M. Magnani,et al. Drug Delivery through Phagocytosis of Red Blood Cells , 2004, Transfusion Medicine and Hemotherapy.
[5] G. Na,et al. Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization , 1999, Pharmaceutical Research.
[6] R. Müller,et al. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908 , 1993 .
[7] M. Dolovich,et al. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.
[8] M. R. Kumar,et al. Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives , 2011 .
[9] I. Ashurst,et al. Pharmaceutical evaluation of a new spacer device for delivery of metered-dose inhalers to infants and young children , 1992 .
[10] Jiesheng Ye,et al. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. , 2008, International journal of pharmaceutics.
[11] P. Uster,et al. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. , 2009, International journal of pharmaceutics.
[12] James L. Little,et al. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS. , 2009, International journal of pharmaceutics.
[13] Yves-Jacques Schneider,et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[14] M. Ghorab,et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.
[15] Dimitra Dodou,et al. Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[16] Böhm,et al. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. , 1999, Pharmaceutical science & technology today.
[17] G Vergnault,et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. , 2007, Advanced drug delivery reviews.
[18] N. Blagden,et al. Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[19] Po-Chang Chiang,et al. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. , 2008, Basic & clinical pharmacology & toxicology.
[20] K. Johnston,et al. In Vivo Efficacy of Aerosolized Nanostructured Itraconazole Formulations for Prevention of Invasive Pulmonary Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.
[21] Rainer H Müller,et al. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[22] R. Müller,et al. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.
[23] W. Forbes,et al. Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics , 1999, Clinical pharmacokinetics.
[24] J. Kreuter,et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.
[25] Rainer H. Müller,et al. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .
[26] A. Weil,et al. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. , 2006, International journal of clinical pharmacology and therapeutics.
[27] J. Remon,et al. In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. , 2002, International journal of pharmaceutics.
[28] R. Müller,et al. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.
[29] Delie,et al. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. , 1998, Advanced drug delivery reviews.
[30] R. Ravichandran. Nanoparticles in Drug Delivery: Potential Green Nanobiomedicine Applications , 2009 .
[31] K Borner,et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. , 2000, The Journal of antimicrobial chemotherapy.
[32] M. Mazzotti,et al. Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. , 2010, International journal of pharmaceutics.
[33] Mo Li,et al. Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs , 2009 .
[34] Patrick Augustijns,et al. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.
[35] Jouni Hirvonen,et al. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods , 2010, The Journal of pharmacy and pharmacology.
[36] Philip S Low,et al. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.
[37] Jonathan Brown,et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. , 2009, International journal of pharmaceutics.
[38] M. Odomi,et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[39] K. Johnston,et al. Enhanced drug dissolution using evaporative precipitation into aqueous solution. , 2002, International journal of pharmaceutics.
[40] G Vergnault,et al. Nanosuspension Formulations for Low-Soluble Drugs: Pharmacokinetic Evaluation Using Spironolactone as Model Compound , 2005, Drug development and industrial pharmacy.
[41] H. Gendelman,et al. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery , 2006, Journal of leukocyte biology.
[42] G. Spedalieri,et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. , 2002, Biomaterials.
[43] R. Müller,et al. Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration , 2002, Pharmaceutical Research.
[44] J. Dressman,et al. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[45] Y. Ikada,et al. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. , 1999, Investigative ophthalmology & visual science.
[46] Jonghwi Lee,et al. Folate-targeted drug-delivery systems prepared by nano-comminution , 2011, Drug development and industrial pharmacy.
[47] Rainer H Müller,et al. Nanocrystal technology, drug delivery and clinical applications , 2008, International journal of nanomedicine.
[48] R. Löbenberg,et al. Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review , 2007 .
[49] Sanjay Garg,et al. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. , 2009, International journal of pharmaceutics.
[50] M. Magnani,et al. Erythrocyte-based drug delivery , 2005, Expert opinion on drug delivery.
[51] Wei Yang,et al. Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.
[52] Shri Kant,et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[53] Xiangrong Song,et al. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. , 2004, International journal of pharmaceutics.
[54] Zhanhu Guo,et al. Surface functionalized alumina nanoparticle filled polymeric nanocomposites with enhanced mechanical properties , 2006 .
[55] A. Voigt,et al. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells. , 2010, Small.
[56] R. Müller,et al. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. , 2005, International journal of pharmaceutics.
[57] R. Langer,et al. Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.
[58] David A Edwards,et al. Bioengineering of therapeutic aerosols. , 2002, Annual review of biomedical engineering.
[59] J. Silverman,et al. Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) , 1999, Pharmaceutical Research.
[60] R. O. Williams,et al. Formulation of a protein with propellant HFA 134a for aerosol delivery. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[61] K. Johnston,et al. Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs , 2004, Drug development and industrial pharmacy.
[62] Qiang Zhang,et al. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. , 2011, Colloids and surfaces. B, Biointerfaces.
[63] Qiang Zhang,et al. In vitro and in vivo antitumor activity of oridonin nanosuspension. , 2009, International journal of pharmaceutics.
[64] Ashim K. Mitra,et al. Recent Perspectives in Ocular Drug Delivery , 2009, Pharmaceutical Research.
[65] Jun Li,et al. Preparation and characterization of intravenously injectable nimodipine nanosuspension. , 2008, International journal of pharmaceutics.
[66] Wenting Dai,et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. , 2008, International journal of pharmaceutics.
[67] Dominique Duchêne,et al. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract , 1997 .
[68] Carmen Popescu,et al. Conversion of Nanosuspensions into Dry Powders by Spray Drying: A Case Study , 2008, Pharmaceutical Research.
[69] Po-Chang Chiang,et al. Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment , 2007, Nanoscale Research Letters.
[70] K. Sigfridsson,et al. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[71] C Olbrich,et al. Formulation of amphotericin B as nanosuspension for oral administration. , 2003, International journal of pharmaceutics.
[72] Aiguo Li,et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer , 2010, Drug development and industrial pharmacy.
[73] D. Andes. In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.
[74] O. Kayser,et al. The impact of nanobiotechnology on the development of new drug delivery systems. , 2005, Current pharmaceutical biotechnology.
[75] J. Kreuter,et al. Use of nanoparticles for cerebral cancer. , 2008, Tumori.
[76] O. Kayser,et al. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. , 2001, International journal of pharmaceutics.
[77] H. Chan,et al. Formation, characterization, and fate of inhaled drug nanoparticles. , 2011, Advanced drug delivery reviews.
[78] O. Kayser,et al. Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[79] Dianrui Zhang,et al. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system , 2008 .
[80] Joseph Wong,et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. , 2007, International journal of pharmaceutics.
[81] H. Gendelman,et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. , 2006, Blood.
[82] Asgar Ali,et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[83] E. R. Cooper,et al. Nanoparticles: A personal experience for formulating poorly water soluble drugs. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[84] Filippos Kesisoglou,et al. Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.
[85] F. Ahmad,et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[86] J. Smart. The basics and underlying mechanisms of mucoadhesion. , 2005, Advanced drug delivery reviews.
[87] Cornelia M Keck,et al. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.
[88] Jean-Michel Kauffmann,et al. The effects of excipients on transporter mediated absorption. , 2010, International journal of pharmaceutics.
[89] A. Lundqvist,et al. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development , 2009, Drug development and industrial pharmacy.
[90] S. Waldman,et al. The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers , 2004, Journal of clinical pharmacology.
[91] J. Engbersen,et al. Polymeric carrier systems for siRNA delivery. , 2012, Current Topics in Medicinal Chemistry.
[92] Barrett E. Rabinow,et al. Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.
[93] M. Magnani,et al. Cell-based drug delivery. , 2008, Advanced drug delivery reviews.
[94] J. Qiu,et al. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. , 2008, International journal of pharmaceutics.
[95] K. Johnston,et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. , 2008, International journal of pharmaceutics.
[96] Forrest M Kievit,et al. Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. , 2011, Advanced drug delivery reviews.
[97] Peter R. Byron,et al. Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.
[98] R. Budden,et al. Experiments on the toxic, sedative and muscle relaxant potency of various drug solvents in mice. , 1979, Pharmacology & therapeutics. Part B: General & systematic pharmacology.
[99] D. Loebenberg,et al. Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis , 2004, Antimicrobial Agents and Chemotherapy.
[100] S. Szefler,et al. Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. , 1999, The Journal of allergy and clinical immunology.
[101] A. Lamprecht,et al. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells , 2006 .
[102] A. Astier,et al. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[103] Kinam Park. To PEGylate or not to PEGylate, that is not the question. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[104] S. Krishnakumar,et al. Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.
[105] G. Liversidge,et al. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .
[106] J. Perfect,et al. SAFETY OF AEROSOLIZED AMPHOTERICIN B LIPID COMPLEX IN LUNG TRANSPLANT RECIPIENTS12 , 2001, Transplantation.
[107] A. C. Hunter,et al. Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[108] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[109] G. Ennas,et al. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. , 2009, International journal of pharmaceutics.
[110] M. Thanou,et al. Targeting nanoparticles to cancer. , 2010, Pharmacological research.
[111] Anna Nordmark,et al. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development , 2011, Drug development and industrial pharmacy.
[112] G. Angioni,et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[113] M. Pratter,et al. The physiologic effects of inhaled amphotericin B. , 1995, Chest.
[114] K. Johnston,et al. Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. , 2007, International journal of pharmaceutics.
[115] R. Herrmann,et al. A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance , 2006, Investigational New Drugs.
[116] Qiang Zhang,et al. Preparation and antitumor study of camptothecin nanocrystals. , 2011, International journal of pharmaceutics.
[117] R. Shegokar,et al. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. , 2011, International journal of pharmaceutics.
[118] Aihua Yu,et al. Preparation and characterization of intravenously injectable curcumin nanosuspension , 2011, Drug delivery.
[119] Gloria Kwei,et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. , 2004, International journal of pharmaceutics.
[120] S. Mitragotri,et al. Identification of Peptide Ligands Facilitating Nanoparticle Attachment to Erythrocytes , 2008, Biotechnology progress.
[121] Pardeep Gupta,et al. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. , 2008, International journal of pharmaceutics.
[122] X. Wu,et al. Nanotechnological advances for the delivery of CNS therapeutics. , 2012, Advanced drug delivery reviews.
[123] K. Johnston,et al. Single dose and multiple dose studies of itraconazole nanoparticles. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[124] Q. Shi,et al. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. , 2006, Biomaterials.
[125] C. Lipinski. Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .
[126] Huibi Xu,et al. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. , 2011, International journal of pharmaceutics.
[127] Dominique Duchêne,et al. Bioadhesion of solid oral dosage forms, why and how? , 1997 .
[128] Jing Ma,et al. Preparation of a chemically stable quercetin formulation using nanosuspension technology. , 2011, International journal of pharmaceutics.
[129] J. Barré,et al. Stealth nanoparticles coated with heparin as peptide or protein carriers , 2009, Journal of drug targeting.
[130] K. Johnston,et al. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[131] Elaine Merisko-Liversidge,et al. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.
[132] R. J. Lee,et al. Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.
[133] J E Kipp,et al. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. , 2004, International journal of pharmaceutics.
[134] J. Perfect,et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients , 2004, Transplantation.
[135] R. Pignatello,et al. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[136] H. Fung,et al. Mechanisms of creatine kinase release from isolated rat skeletal muscles damaged by propylene glycol and ethanol. , 1990, Journal of pharmaceutical sciences.
[137] A F Thünemann,et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. , 2006, International journal of pharmaceutics.
[138] G. Liversidge,et al. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .
[139] Elaine Merisko-Liversidge,et al. Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[140] F. Liu,et al. Targeted cancer therapy with novel high drug-loading nanocrystals. , 2010, Journal of pharmaceutical sciences.
[141] K. Korttila,et al. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. , 2009, Acta pharmacologica et toxicologica.
[142] Y. Lai,et al. Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery , 2009, Nanoscale research letters.
[143] M. Heimesaat,et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers , 2011, Journal of drug targeting.
[144] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[145] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[146] K. Johnston,et al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. , 2007, The Journal of infection.
[147] G. Olmos,et al. Delivery to macrophages and toxic action of etoposide carried in mouse red blood cells. , 2003, Biochimica et biophysica acta.
[148] P. Vavia,et al. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. , 2009, Nanomedicine : nanotechnology, biology, and medicine.
[149] R. Alyautdin,et al. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles , 1997 .
[150] Yun-Seok Rhee,et al. Nanomedicine in pulmonary delivery , 2009, International journal of nanomedicine.
[151] Robert J. Lee,et al. Targeted drug delivery via folate receptors , 2008, Expert opinion on drug delivery.
[152] J. Kreuter,et al. Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.
[153] G. Sharma,et al. Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.